Results 21 to 30 of about 72,871 (224)

Personalizing HIV therapy, mission impossible? [PDF]

open access: yes, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

open access: yesТерапевтический архив, 2021
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of ...
Natalia Yu. Pshenichnaya   +17 more
doaj   +1 more source

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence

open access: yesInfectious Disease Reports, 2023
Vaccines remain the cornerstone of medical prevention and are highly effective in reducing the risk of severe disease and death due to coronavirus disease 2019 (COVID-19).
Ioannis Karniadakis   +5 more
doaj   +1 more source

Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents [PDF]

open access: yes, 2017
Hepatitis C virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinaemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality.
Burra, Patrizia   +13 more
core   +1 more source

In-vitro effects of protease inhibitors on BAX, BCL-2 and apoptosis in two human breast cell lines (with corrigendum)

open access: yesSouth African Journal of Science, 2015
Currently, the treatment of choice of HIV/AIDS in South Africa is the multidrug combination regimen known as HAART (highly active antiretroviral treatment).
Gbenga A. Adefolaju   +2 more
doaj   +1 more source

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019 [PDF]

open access: yesThe Korean Journal of Internal Medicine, 2021
Background/Aims The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19).
Ji-Won Kim   +6 more
doaj   +1 more source

Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients

open access: yesAnnals of Hepatology, 2019
Introduction and aim. We assessed the characteristics of virological response to a combination treatment of ombitasvir, paritaprevir, and ritonavir in hepatitis C virus genotype 1-infected elderly Japanese patients.Material and Methods.
Haruki Uojima   +11 more
doaj   +1 more source

Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir. [PDF]

open access: yes, 2014
INTRODUCTION: There are few data regarding the tolerability, safety, or efficacy of antenatal atazanavir. We report our clinical experience of atazanavir use in pregnancy.
Anderson, J   +24 more
core   +2 more sources

Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking

open access: yesBioTechniques, 2020
The outbreak of viral pneumonia caused by the novel coronavirus SARS-CoV-2 that began in December 2019 caused high mortality. It has been suggested that the main protease (Mpro) of SARS-CoV-2 may be an important target to discover pharmaceutical ...
Bijun Cheng, Tianjiao Li
doaj   +1 more source

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]

open access: yes, 2019
Background The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks.
Al-Ali, Anfal Y.   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy